Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06590194 | PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 / Phase 2 | 96 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT05222087 | PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study(PRIME_LUNG) | unknown | Phase 1 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06479473 | Radiotherapy to All Residual Lesions After Chemoimmunotherapy | unknown | Phase 1 / Phase 2 | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05183243 | GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results | unknown | Phase 1 | 68 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05271292 | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.(SCLC) | unknown | Phase 1 / Phase 2 | 36 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06362980 | A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations(EGFR) | unknown | Phase 1 | 20 | National Cancer Center, ChinaOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | unknown | Phase 1 | 63 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Jun 27, 2024 | clinicaltrials |
| NCT05816499 | Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)(AK104IIT018) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT04818333 | A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT05240131 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 1 / Phase 2 | 88 | Galecto Biotech ABINDUSTRY | 3 | Apr 12, 2024 | clinicaltrials |
| NCT05519293 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05552781 | H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04772235 | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients(TOTEM) | unknown | Phase 1 | 32 | Instituto Oncológico Dr RosellOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06281860 | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration(PITHAC) | unknown | Phase 1 | 39 | Dr Jean Yannis PERENTESOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03274479 | PBF-1129 in Patients With NSCLC | unknown | Phase 1 | 18 | Palobiofarma SLINDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06239623 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | unknown | Phase 1 | 60 | JS InnoPharm, LLCINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05573373 | Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06187740 | Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | unknown | Phase 1 | 28 | Fudan UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04253145 | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 184 | Fundacion OncosurNETWORK | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06136910 | Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05451173 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | unknown | Phase 1 / Phase 2 | 83 | Alexander ChiOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05728619 | HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 64 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05347628 | Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 91 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05102214 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05978401 | Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 152 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05975944 | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05965102 | Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer | unknown | Phase 1 | 31 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jul 28, 2023 | clinicaltrials |
| NCT05731518 | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | unknown | Phase 1 / Phase 2 | 67 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05489731 | VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer(VIC-1911) | unknown | Phase 1 | 72 | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.OTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05780307 | IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors | unknown | Phase 1 | 48 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT05498389 | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | unknown | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT03797391 | A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 186 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | May 31, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Dec 18, 2024source: clinicaltrials